Obesity May Attenuate Anti-TNF Response in Psoriatic Arthritis
Key clinical point: Obesity may reduce response and adherence to tumor necrosis factor–inhibitor therapy in patients with psoriatic arthritis.
Major finding: The EULAR good or moderate response rate at 6 months was 55% in obese vs. 65% in nonobese patients (P = .02).
Data source: Observational cohort study based on two Nordic registries of 1,943 patients with PsA prescribed their first TNFi.
Disclosures: DANBIO is supported by unrestricted grants from Abbott, Pfizer, MSD, Bristol-Myers Squibb, Roche, and UCB-Nordic. The sponsors have had no influence on data collection, analysis, or publication. ICEBIO is part of the electronic medical record system held by the University of Reykjavik and receives no industrial funding. Ms. Højgaard has received speaking fees from Celgene and UCB not related to this work.
DANBIO is supported by unrestricted grants from Abbott, Pfizer, MSD, Bristol-Myers Squibb, Roche, and UCB-Nordic. The sponsors have had no influence on data collection, analysis, or publication. ICEBIO is part of the electronic medical record system held by the University of Reykjavik and receives no industrial funding. Ms. Højgaard has received speaking fees from Celgene and UCB not related to this work.
